| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 01/02/2004 | EP1373506A2 Yeast strain of saccharomyces cerevisiae with functional expression of a glut transporter |
| 01/02/2004 | EP1373504A2 Mammalian tribbles signaling pathways and methods and reagents related thereto |
| 01/02/2004 | EP1373489A2 Human dual specificity protein phosphatase 7-like protein |
| 01/02/2004 | EP1373485A2 Ikk2 variant, dino gene, lectin-like receptor gene, and proteins encoded thereby |
| 01/02/2004 | EP1373321A2 Modified antibodies and methods of use |
| 01/02/2004 | EP1373318A2 Neutralizing human monoclonal antibodies against hiv-1, their production and uses |
| 01/02/2004 | EP1373317A2 Nuclear hormone receptor ligand binding domains |
| 01/02/2004 | EP1373316A2 Nuclear hormone receptor ligand binding domain |
| 01/02/2004 | EP1373315A2 Nuclear hormone receptor ligand binding domain |
| 01/02/2004 | EP1373306A2 Cytoskeletion-associated proteins |
| 01/02/2004 | EP1373303A1 Novel peptide ligands of leukocyte integrins |
| 01/02/2004 | EP1373301A2 Reducing the immunogenicity of fusion proteins |
| 01/02/2004 | EP1373269A1 Jun kinase inhibitors |
| 01/02/2004 | EP1373257A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| 01/02/2004 | EP1373252A1 Chemical derivatives and their use as anti-telomerase agent |
| 01/02/2004 | EP1373240A2 Retinoid x receptor modulators |
| 01/02/2004 | EP1373234A2 Urokinase inhibitors |
| 01/02/2004 | EP1373223A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
| 01/02/2004 | EP1373220A1 Benzimidazoles that are useful in treating sexual dysfunction |
| 01/02/2004 | EP1373206A1 Aryl oxime-piperazines useful as ccr5 antagonists |
| 01/02/2004 | EP1373203A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| 01/02/2004 | EP1373192A1 N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad |
| 01/02/2004 | EP1372785A2 Compositions having improved bioavailability of eletriptan |
| 01/02/2004 | EP1372741A2 Morpholino imaging and therapy |
| 01/02/2004 | EP1372738A1 Increasing retrievable fluid from a breast duct |
| 01/02/2004 | EP1372737A2 Preparation for the prophylaxis of restenosis |
| 01/02/2004 | EP1372735A2 Conjugate of hydroxyalkyl starch and an active agent |
| 01/02/2004 | EP1372725A1 Compositions and methods for non-insulin glucose uptake |
| 01/02/2004 | EP1372724A2 Use of immunoregulatory antibodies in the treatment of neoplastic disorders |
| 01/02/2004 | EP1372720A1 Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists |
| 01/02/2004 | EP1372717A2 Combination treatment of pancreatic cancer |
| 01/02/2004 | EP1372716A2 Blood cell production via activation of the hemoglobin scavenger receptor (cd163) |
| 01/02/2004 | EP1372715A2 Method for treating cancer using a33 specific antibodies and chemotherapeutic agents |
| 01/02/2004 | EP1372712A2 Equine herpesvirus vaccine |
| 01/02/2004 | EP1372701A2 Methods of therapy for hiv infection |
| 01/02/2004 | EP1372698A2 Use of cytokines of the tgf-beta superfamily for the treatment and diagnosis of skin related disorders |
| 01/02/2004 | EP1372696A2 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 01/02/2004 | EP1372690A2 93870, a human g-protein coupled receptor and uses therefor |
| 01/02/2004 | EP1372689A2 Use of ikk-beta inhibitors and method for discovery of said inhibitors |
| 01/02/2004 | EP1372677A1 Antitumor methods and compositions comprising sesquiterpene derivatives |
| 01/02/2004 | EP1372673A2 The use of non-digestible polymeric foams to sequester ingested materials, thereby inhibiting their absorption by the body |
| 01/02/2004 | EP1372671A2 Methylated promoters for intraductal treatment of breast cancer |
| 01/02/2004 | EP1372666A1 Use of fluticasone propionate in the treatment of diseases ameliorated by enhancement of epithelial / matrix adhesion such as asthma, cystic fibrosis and influenza |
| 01/02/2004 | EP1372665A2 Hormone replacement therapy method and its administration form |
| 01/02/2004 | EP1372663A1 Therapeutical method involving subcutaneous administration of drugs containing cephalotaxine derivatives |
| 01/02/2004 | EP1372660A2 A combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes |
| 01/02/2004 | EP1372658A2 Methods of treating cancer using cyplastin combined with a dioxolane nucleoside such as troxacitabine |
| 01/02/2004 | EP1372657A2 A method of treating proliferative diseases using eg5 inhibitors |
| 01/02/2004 | EP1372655A2 Cathepsin cysteine protease inhibitors |
| 01/02/2004 | EP1372653A2 Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| 01/02/2004 | EP1372652A2 Combination of a taxane and a cyclin-dependent kinase |
| 01/02/2004 | EP1372650A2 Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative |
| 01/02/2004 | EP1372649A2 Novel medicament compositions on the basis of anticholinergics and pde iv inhibitors |
| 01/02/2004 | EP1372646A2 Use of sugar phosphates, sugar phosphate analogues, amino acids, amino acid analoges for modulating transaminases and/or the association of p36/malate dehydrogenase |
| 01/02/2004 | EP1372645A1 Reconstitutable parenteral composition containing a cox-2 inhibitor |
| 01/02/2004 | EP1372641A1 Enteral formulation |
| 01/02/2004 | EP1372639A2 Agent for the treatment of bladder irritative symptoms accompanied by benign prostatic hyperplasia |
| 01/02/2004 | EP1372638A1 Functional role for cannabinoids in autonomic stability during sleep |
| 01/02/2004 | EP1372636A2 Metronomic dosing of taxanes for inhibiting tumor growth |
| 01/02/2004 | EP1372632A1 Proliferative activator receptor (ppar) compounds |
| 01/02/2004 | EP1372630A2 Agent for the treatment of overactive bladder |
| 01/02/2004 | EP1372628A2 Paracetamol solutions which are stable in storage and ready for infusion |
| 01/02/2004 | EP1372626A1 Compositions and methods for enhancing drug delivery across and into ocular tissues |
| 01/02/2004 | EP1372620A2 Methods for restoring cognitive function following systemic stress |
| 01/02/2004 | EP1372615A1 Compounds and compositions for delivering active agents |
| 01/02/2004 | EP1372610A2 Powder inhaler formulations |
| 01/02/2004 | EP1372571A2 Method and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds |
| 01/02/2004 | EP1372529A2 Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation |
| 01/02/2004 | EP1372412A2 Composition improving age-related physiological deficits and increasing longevity |
| 01/02/2004 | EP1250146B1 Use of botulinum toxins for treating diabetes |
| 01/02/2004 | EP1235830B1 PYRROLO[2,3-d]PYRIMIDINE COMPOUNDS AS PROTEIN KINASES INHIBITORS |
| 01/01/2004 | US20040003425 Nav2 channel gene-deficient non-human animals |
| 01/01/2004 | US20040003422 An expression cassette containing the proopiomelanocortin (POMC) enhancer, and a nucleic acid sequence encoding POMC contains at least one exon, wherein a polylinker having an unique site for restriction enzyme is inserted into the exon; gene regulates weight and fat mass |
| 01/01/2004 | US20040002548 Therapy for respiratory system disorders |
| 01/01/2004 | US20040002544 Antidiabetic preparation for oral administration |
| 01/01/2004 | US20040002543 Synergistic mixture |
| 01/01/2004 | US20040002540 Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| 01/01/2004 | US20040002537 Multiple sclerosis; central nervous system disorders; side effect reduction |
| 01/01/2004 | US20040002535 Methods of treating hormone-related conditions using thio-oxindole derivatives |
| 01/01/2004 | US20040002529 Mixture with diuretics; hypotensive agents |
| 01/01/2004 | US20040002524 Cardiovascular disorders; osteoporosis; central nervous system disorders |
| 01/01/2004 | US20040002522 Antiinflammatory agents; analgesics |
| 01/01/2004 | US20040002519 Mixture of hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, insulin elimination promoter and insulin sensitizer with carrier |
| 01/01/2004 | US20040002503 Compositions and methods for combating lower urinary tract dysfunctions with delta opioid receptor agonists |
| 01/01/2004 | US20040002502 Respiratory system disorders; antiinflammatory agents |
| 01/01/2004 | US20040002499 Antitumor agents; anticancer agents; mixture of curcumin and paclitaxel |
| 01/01/2004 | US20040002498 Tricyclic compounds useful as HIV reverse transcriptase inhibitors |
| 01/01/2004 | US20040002495 Lactam glycogen phosphorylase inhibitors and method of use |
| 01/01/2004 | US20040002494 Substituted polycyclic aryl and heteroaryl pyridines useful for selective inhibition of the coagulation cascade |
| 01/01/2004 | US20040002479 Proteasome inhibitors; bone disorders |
| 01/01/2004 | US20040002476 Modified fluorinated nucleoside analogues |
| 01/01/2004 | US20040002466 Releasing interferon from complex of interferon and nucleic acids; antitumor agents, viricide, induction immunology response |
| 01/01/2004 | US20040002460 Spheron components useful in determining compounds capable of treating symptoms of Alzheimer's disease, and treatments and animal models produced therefrom |
| 01/01/2004 | US20040002454 Administering polypeptides; cardiovascular disorders |
| 01/01/2004 | US20040002447 Induction of insulin expression |
| 01/01/2004 | US20040002439 Human voltage gated sodium channel beta1A subunit and methods of use |
| 01/01/2004 | US20040002114 Nucleic acids encoding a G-protein coupled receptor involved in islet cell signaling |
| 01/01/2004 | US20040002088 Identification and isolation of novel DNA and to the recombinant production of polypeptides having sequence similarity to Glial Cell line-derived Neurotrophic Factor Receptor (GDNFR) |
| 01/01/2004 | US20040001898 Fermentated dietetic fibers; anticancer agents |
| 01/01/2004 | US20040001897 Skin vitalizing composition for external use anti-aging preparation |